APA (7th ed.) Citation

Costa-Frossard, L., Brieva, L., García-Estévez, D. A., Martín-Martínez, J. M., Álvarez-Bravo, G., Blasco-Quílez, M. R., . . . Gascón-Giménez, F. (2026). Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis. International Journal of Molecular Sciences, 27(11), 4933. https://doi.org/10.3390/ijms27114933

Chicago Style (17th ed.) Citation

Costa-Frossard, Lucienne, et al. "Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis." International Journal of Molecular Sciences 27, no. 11 (2026): 4933. https://doi.org/10.3390/ijms27114933.

MLA (9th ed.) Citation

Costa-Frossard, Lucienne, et al. "Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis." International Journal of Molecular Sciences, vol. 27, no. 11, 2026, p. 4933, https://doi.org/10.3390/ijms27114933.